Exploratory clinical trial of combination wound therapy with a gelatin sheet and platelet-rich plasma in patients with chronic skin ulcers: study protocol

Abstract

IntroductionChronic skin ulcers, such as diabetic ulcers, venous leg ulcers and pressure ulcers, are intractable and increasing in prevalence, representing a costly problem in healthcare. We developed a combination therapy with a gelatin sheet, capable of providing sustained release of platelet-rich plasma (PRP). The objective of this study is to investigate the safety and efficacy of autologous PRP covered with a hydrocolloid dressing and PRP covered with a gelatin sheet in the treatment of chronic skin ulcers.Methods and analysisThirty patients with chronic skin ulcers who have not healed with conventional therapy for at least 1 month are being recruited. The patients will receive PRP after debridement, and the wounds will be covered with a hydrocolloid dressing or gelatin sheet. The efficacy will be evaluated according to the time from the beginning of PRP application to secondary healing or the day on which wound closure is achieved with a relatively simple surgical procedure, such as skin grafting or suturing. All patients will be followed up until 6 weeks after application to observe adverse events related to the application of PRP and the dressings. This study was designed to address and compare the safety and efficacy of PRP covered with a hydrocolloid dressing versus a gelatin sheet. If successful, this combination therapy may be an alternative to bioengineered skin substitutes containing living cells and lead to substantial progress in the management of chronic skin ulcers.Ethics and disseminationThe study protocol was approved by the Institutional Review Board of Kansai Medical University (KMU Number 0649-1, 4 August 2014: V.1.0). The findings of this trial will be disseminated through peer-reviewed journals, and national and international scientific meetings as well as to the patients.Trial registration numberUMIN000015689.

Mesenchymal Stem Cells in Chronic Wounds: The Spectrum from Basic to Advanced Therapy

“…70 In Japan, human recombinant basic fibroblast growth factor (bFGF) (Kaken Pharmaceutical, Tokyo, Japan) is in use since 2001. bFGF stimulates fibroblasts and blood vessel formation. 71,72 Several studies have shown the effectiveness of recombinant human epidermal growth factor (rhEGF) in both diabetic foot ulcers and venous chronic wounds.…”

Alternative method of treating prolonged wound defects of trunk and extremities

“…The other important signaling molecule produced by both keratinocytes and fibroblasts is TGF-β. Its expression induces the formation of granulation tissue, reepithelization and tissue reconstruction [5].…”

The use of artificial dermis for corrective surgery on burn scars

“…Moreover, this artificial dermis was developed for use in various indications. Growth factor was loaded into the inner layer, which can accelerate chronic wound healing and prolong its stability [12,13]. The artificial dermis is impregnated with an antibiotic for application on contaminated wounds [14].…”